(NASDAQ: JANX) Janux Therapeutics's forecast annual revenue growth rate of 131.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Janux Therapeutics's revenue in 2024 is $8,083,000.On average, 2 Wall Street analysts forecast JANX's revenue for 2024 to be $125,792,246, with the lowest JANX revenue forecast at $87,822,102, and the highest JANX revenue forecast at $163,762,390. On average, 1 Wall Street analysts forecast JANX's revenue for 2027 to be $599,256,696, with the lowest JANX revenue forecast at $599,256,696, and the highest JANX revenue forecast at $599,256,696.
In 2028, JANX is forecast to generate $6,134,115,524 in revenue, with the lowest revenue forecast at $6,134,115,524 and the highest revenue forecast at $6,134,115,524.